Current understanding of the mechanism of HPV infection

Gynecologic Oncology

Volumn 118, Issue 1 SUPPL. 1, 2010, Pages

  Schiller, John T ^a   Day, Patricia M ^a   Kines, Rhonda C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

HPV antibodies; HPV binding; HPV entry; HPV infection cycle; HPV intracellular trafficking

Indexed keywords

CAPSID PROTEIN L1; CELL SURFACE RECEPTOR; FURIN; NEUTRALIZING ANTIBODY; PROTEOHEPARAN SULFATE; WART VIRUS VACCINE;

AMINO TERMINAL SEQUENCE; BASAL CELL; BASEMENT MEMBRANE; CELL CULTURE; CELL DIVISION; CELL MIGRATION; CELL SURFACE; CONDYLOMA ACUMINATUM; CONFORMATIONAL TRANSITION; DRUG EFFICACY; ENDOSOME; EPITHELIUM; EXPERIMENTAL MODEL; HUMAN; IN VIVO STUDY; INTERNALIZATION; KERATINOCYTE; NONHUMAN; PAPILLOMA VIRUS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN TRANSPORT; RECEPTOR BINDING; REVIEW; TISSUE INJURY; TRANSCRIPTION INITIATION; UTERINE CERVIX CANCER; VIRION; VIRUS ATTACHMENT; VIRUS GENE; WART VIRUS;

ALPHAPAPILLOMAVIRUS; ANIMALS; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 77952306622     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.04.004     Document Type: Review

References (59)

1. Kirnbauer R., Booy F., Cheng N., Lowy D.R., and Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89 (1992) 12180-12184
2. Meyers C., Frattini M.G., Hudson J.B., and Laimins L.A. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 257 (1992) 971-973
3. Buck C.B., Pastrana D.V., Lowy D.R., and Schiller J.T. Efficient intracellular assembly of papillomaviral vectors. J Virol 78 (2004) 751-757
4. Roberts J.N., Buck C.B., Thompson C.D., Kines R., Bernardo M., Choyke P.L., et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13 (2007) 857-861
5. Roden R.B., Kirnbauer R., Jenson A.B., Lowy D.R., and Schiller J.T. Interaction of papillomaviruses with the cell surface. J Virol 68 (1994) 7260-7266
6. Joyce J.G., Tung J.S., Przysiecki C.T., Cook J.C., Lehman E.D., Sands J.A., et al. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 274 (1999) 5810-5822
7. Giroglou T., Florin L., Schafer F., Streeck R.E., and Sapp M. Human papillomavirus infection requires cell surface heparan sulfate. J Virol 75 (2001) 1565-1570
8. Buck C.B., Thompson C.D., Roberts J.N., Muller M., Lowy D.R., and Schiller J.T. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2 (2006) e69
9. Patterson N.A., Smith J.L., and Ozbun M.A. Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate. J Virol 79 (2005) 6838-6847
10. Culp T.D., Budgeon L.R., and Christensen N.D. Human papillomaviruses bind a basal extracellular matrix component secreted by keratinocytes which is distinct from a membrane-associated receptor. Virology 347 (2006) 147-159
11. Culp T.D., Budgeon L.R., Marinkovich M.P., Meneguzzi G., and Christensen N.D. Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells. J Virol 80 (2006) 8940-8950
12. Selinka H.C., Florin L., Patel H.D., Freitag K., Schmidtke M., Makarov V.A., et al. Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J Virol 81 (2007) 10970-10980
13. Day P.M., Lowy D.R., and Schiller J.T. Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids. J Virol 82 (2008) 12565-12568
14. Johnson K.M., Kines R.C., Roberts J.N., Lowy D.R., Schiller J.T., and Day P.M. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 83 (2009) 2067-2074
15. Selinka H.C., Giroglou T., Nowak T., Christensen N.D., and Sapp M. Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol 77 (2003) 12961-12967
16. Campo M.S., Jarrett W.F., O'Neil W., and Barron R.J. Latent papillomavirus infection in cattle. Res Vet Sci 56 (1994) 151-157
17. Da Silva D.M., Velders M.P., Nieland J.D., Schiller J.T., Nickoloff B.J., and Kast W.M. Physical interaction of human papillomavirus virus-like particles with immune cells. Int Immunol 13 (2001) 633-641
18. Lenz P., Day P.M., Pang Y.Y., Frye S.A., Jensen P.N., Lowy D.R., et al. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 166 (2001) 5346-5355
19. Fausch S.C., Da Silva D.M., and Kast W.M. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res 63 (2003) 3478-3482
20. Day P.M., Lowy D.R., and Schiller J.T. Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 307 (2003) 1-11
21. Christensen N.D., Cladel N.M., and Reed C.A. Postattachment neutralization of papillomaviruses by monoclonal and polyclonal antibodies. Virology 207 (1995) 136-142
22. Culp T.D., and Christensen N.D. Kinetics of in vitro adsorption and entry of papillomavirus virions. Virology 319 (2004) 152-161
23. Richards R.M., Lowy D.R., Schiller J.T., and Day P.M. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A 103 (2006) 1522-1527
24. Kines R.C., Thompson C.D., Lowy D.R., Schiller J.T., and Day P.M. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A 106 (2009) 20458-20463
25. Buck C.B., Thompson C.D., Pang Y.Y., Lowy D.R., and Schiller J.T. Maturation of papillomavirus capsids. J Virol 79 (2005) 2839-2846
26. Evander M., Frazer I.H., Payne E., Qi Y.M., Hengst K., and McMillan N.A. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J Virol 71 (1997) 2449-2456
27. Sibbet G., Romero-Graillet C., Meneguzzi G., and Campo M.S. Alpha6 integrin is not the obligatory cell receptor for bovine papillomavirus type 4. J Gen Virol 81 (2000) 327-334
28. Shafti-Keramat S., Handisurya A., Kriehuber E., Meneguzzi G., Slupetzky K., and Kirnbauer R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 77 (2003) 13125-13135
29. Schelhaas M., Ewers H., Rajamaki M.L., Day P.M., Schiller J.T., and Helenius A. Human papillomavirus type 16 entry: retrograde cell surface transport along actin-rich protrusions. PLoS Pathog 4 (2008) e1000148
30. Smith J.L., Lidke D.S., and Ozbun M.A. Virus activated filopodia promote human papillomavirus type 31 uptake from the extracellular matrix. Virology 381 (2008) 16-21
31. Hindmarsh P.L., and Laimins L.A. Mechanisms regulating expression of the HPV 31 L1 and L2 capsid proteins and pseudovirion entry. J Virol 4 (2007) 19
32. Laniosz V., Holthusen K.A., and Meneses P.I. Bovine papillomavirus type 1: from clathrin to caveolin. J Virol 82 (2008) 6288-6298
33. Bousarghin L., Touze A., Sizaret P.Y., and Coursaget P. Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells. J Virol 77 (2003) 3846-3850
34. Smith J.L., Campos S.K., and Ozbun M.A. Human papillomavirus type 31 uses a caveolin 1- and dynamin 2-mediated entry pathway for infection of human keratinocytes. J Virol 81 (2007) 9922-9931
35. Spoden G., Freitag K., Husmann M., Boller K., Sapp M., Lambert C., et al. Clathrin- and caveolin-independent entry of human papillomavirus type 16-involvement of tetraspanin-enriched microdomains (TEMs). PLoS ONE 3 (2008) e3313
36. Day P.M., Baker C.C., Lowy D.R., and Schiller J.T. Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc Natl Acad Sci U S A 101 (2004) 14252-14257
37. Kamper N., Day P.M., Nowak T., Selinka H.C., Florin L., Bolscher J., et al. A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J Virol 80 (2006) 759-768
38. Selinka H.C., Giroglou T., and Sapp M. Analysis of the infectious entry pathway of human papillomavirus type 33 pseudovirions. Virology 299 (2002) 279-287
39. Florin L., Becker K.A., Lambert C., Nowak T., Sapp C., Strand D., et al. Identification of a dynein interacting domain in the papillomavirus minor capsid protein L2. J Virol 80 (2006) 6691-6696
40. Pyeon D., Pearce S.M., Lank S.M., Ahlquist P., and Lambert P.F. Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog 5 (2009) e1000318
41. Darshan M.S., Lucchi J., Harding E., and Moroianu J. The L2 minor capsid protein of human papillomavirus type 16 interacts with a network of nuclear import receptors. J Virol 78 (2004) 12179-12188
42. Maul G. Nuclear domain 10, the site of DNA virus transcription and replication. Bioessays 20 (1998) 660-667
43. Everett R. DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene 20 (2001) 7266-7273
44. Florin L., Schafer F., Sotlar K., Streeck R.E., and Sapp M. Reorganization of nuclear domain 10 induced by papillomavirus capsid protein L2. Virology 295 (2002) 97-107
45. Schiller J.T., and Lowy D.L. Prospects for cervical cancer prevention by human papillomavirus vaccination. Cancer Res 66 (2006) 10229-10232
46. Schiller J.T., Castellsagué X., Villa L.L., and Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26 (2008) K53-K61 Suppl 10
47. Schiller J.T., and Lowy D.L. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 200 (2009) 166-171
48. Breitburd F.K.R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., Schiller J.T., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69 (1995) 3959-3963
49. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 92 (1995) 11553-11557
50. Day P.M., Thompson C.D., Buck C.B., Pang Y.Y., Lowy D.R., and Schiller J.T. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol 81 (2007) 8784-8792
51. Day P.M., Gambhira R., Roden R.B., Lowy D.R., and Schiller J.T. Mechanisms of human papillomavirus type 16 neutralization by L2 cross-neutralizing and L1 type-specific antibodies. J Virol 82 (2008) 4638-4646
52. Pastrana D.V., Gambhira R., Buck C.B., Pang Y.Y., Thompson C.D., Culp T.D., et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337 (2005) 365-372
53. Roden R.B., Yutzy IV W.H., Fallon R., Inglis S., Lowy D.R., and Schiller J.T. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270 (2000) 254-257
54. Gambhira R., Karanam B., Jagu S., Roberts J.N., Buck C.B., Bossis I., et al. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 81 (2007) 13927-13931
55. Alphs H.H., Gambhira R., Karanam B., Roberts J.N., Jagu S., Schiller J.T., et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A 105 (2008) 5850-5855
56. Kawana Y., Kawana K., Yoshikawa H., Taketani Y., Yoshiike K., and Kanda T. Human papillomavirus type 16 minor capsid protein L2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. J Virol 75 (2001) 2331-2336
57. Kondo K., Ishii Y., Ochi H., Matsumoto T., Yoshikawa H., and Kanda T. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 358 (2007) 266-272
58. Jagu S., Karanam B., Gambhira R., Chivukula S.V., Chaganti R.J., Lowy D.R., et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 101 (2009) 782-792
59. Phogat S., Wyatt R.T., and Karlsson Hedestam G.B. Inhibition of HIV-1 entry antibodies: potential viral and cellular targets. J Intern Med 262 (2007) 26-43